Klinefelter syndrome linked to higher diabetes rates
Danish registry records linked diagnosis and testosterone treatment status to differing metabolic profiles, without establishing treatment benefits.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Men with Klinefelter syndrome had higher diabetes incidence than male controls. Undiagnosed men had the most severe metabolic profile, including more obesity and advanced diabetes complications than treated men. These associations cannot show that testosterone improved outcomes or establish that one way of giving it was safer.
This abstract-based summary cannot establish treatment effects. Absolute diabetes risks are not reported, and the available methods do not allow an assessment of remaining confounding.
What researchers found
New type 2 diabetes diagnoses
During January 1994–December 2022, the estimated diagnosis rate among men still without diabetes was 2.56 times as high with Klinefelter syndrome as in male controls. This compares rates at a given time, not the overall chance of developing diabetes. The interval’s confidence level was not specified.
Treatment routes showed mixed patterns
Injectable testosterone was associated with less obesity and diabetes but more high blood pressure and high cholesterol than skin-applied testosterone. This mixed pattern does not identify an overall better route.
Mortality results need care
After diabetes diagnosis, mortality was higher in diagnosed but untreated men than in controls. Treated men did not differ significantly from controls; that finding does not establish equal mortality or prove a treatment benefit.
The original publication
Metabolism and Type 2 Diabetes Across Life Stages in Klinefelter Syndrome: A Population-Based Cohort Study.
Chang S, Pedersen L, Skakkebæk A et al.
J Clin Endocrinol Metab · 2026
- PubMed ID
- 41237827
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.